It was a rough ride for the Big Four banks as well as the markets over the past five days, with Bank of America (NYSE: BAC ) in particular down 3.48% for the week at the start of the last day of trading. Promising jobs news from the federal government today looks set to keep Thursday's late rally in motion, but B of A has a lot of ground to try to make up, and the major trial currently underway isn't helping things.
Mixed messages
The Labor Department is reporting that the U.S. economy added 175,000 new jobs in May, beating expectations. The unemployment rate rose from 7.5% to 7.6%, but this is because more people are returning to the workforce.�This is the good news.
The bad news is that B of A is in the middle of a trial in which tens of billions of dollars are potentially at stake. On Monday, opening arguments began in a case that pits B of A against, among others, AIG (NYSE: AIG ) , over bad mortgage-backed securities issued by Countrywide Financial, the subprime lender B of A acquired in 2008.
Best Consumer Companies To Watch For 2015: Buhler Industries Inc (BIIAF.PK)
Buhler Industries Inc. is a manufacturer of a range of agricultural equipment marketed throughout North America under three primary brand names Versatile, Allied, and Farm King. The Company�� principal products are tractors, self-propelled and pull-type sprayers, frontend loaders, grain augers, snow blowers, tillers, finishing mowers, feed processing equipment, seeding and tillage equipment and hay and forage equipment. The Company�� factories include the Winnipeg (Clarence) factory, the Morden, Manitoba factory, the Winnipeg (Regent) factory, the Bradley Steel Processors��factory, the Fargo factory, the Salem factory, the Willmar factory and the Vegreville factory. The Company�� subsidiaries include John Buhler Inc., Progressive Manufacturing Ltd., Amarillo Service & Supply Inc., Haskett Properties Inc., Buhler Versatile Inc, Haskett Investments Ltd., Buhler Finance Inc. and Buhler Ezee-On, Inc. Advisors' Opinion:- [By Seth Barkett]
Buhler Industries Inc. (BIIAF.PK) is headquartered in Winnipeg, Manitoba, Canada. The company was established in 1932 as an agricultural equipment manufacturer. It was purchased by John Buhler in 1969 and in 2007, Combine Factory Rostselmash Ltd. acquired 80% of the company's stock. Through steady expansion, new products and distribution channels, and acquisitions, Buhler has experienced impressive growth. With seven manufacturing plants across Canada and the United States as well as a great collection of brands like Farm King, Allied, Inland, and Versatile, this vertically-integrated manufacturer is an excellent way to invest in the global agricultural boom.
Top 10 High Tech Companies To Buy For 2014: Elray Resources Inc (ELRA)
Elray Resources, Inc., incorporated on December 13, 2006, is an exploration stage company. The Company was engaged in the acquisition and exploration of mineral properties with a view to exploiting any mineral deposits discovered.
Elray owned a 100% interest in Porphyry Creek, a 90 square kilometer gold and copper claim located in Cambodia. During the year ended December 31, 2011, the Company has not generated any revenues.
Advisors' Opinion:- [By Peter Graham]
Small cap entertainment or gaming stocks Soul and Vibe Interactive Inc (OTCBB: SOUL), Elray Resources Inc (OTCMKTS: ELRA) and Players Network (OTCMKTS: PNTV) focus on entertaining consumers. However, its important to remember that consumers can be very fickle when it comes to entertainment or games. So should you be entertaining any of these small caps? Here is a closer look and a reality check:
Top 10 High Tech Companies To Buy For 2014: Northrim BanCorp Inc(NRIM)
Northrim BanCorp, Inc., through its subsidiaries, which provides a range of banking products and services to businesses, professionals, and individuals in Alaska. Its deposit services include noninterest-bearing checking accounts and interest-bearing time deposits, checking accounts, and savings accounts. The company?s loan portfolio comprises commercial and real estate lending, construction and land development lending, and consumer loans. Northrim BanCorp also offers other customer services, including telebanking, faxed account statements, Internet banking, automated teller services, personalized checks at account opening, overdraft protection from a savings account, extended banking hours, commercial drive-up banking with coin service, automatic transfers and payments, wire transfers, direct payroll deposit, electronic tax payments, automated clearing house origination and receipt, and cash management services. In addition, it provides investment advisory, insurance br okerage, trust, and wealth management services. As of December 31, 2009, the company operated 11 branches, including 7 in Anchorage, 2 in Fairbanks, and 1 each in Eagle River and Wasilla. Northrim BanCorp, Inc. was founded in 1990 and is headquartered in Anchorage, Alaska.
Advisors' Opinion:- [By GURUFOCUS]
Northrim BanCorp Inc. (NRIM) operates as the bank holding company for Northrim Bank that provides commercial banking products and services to businesses, professionals, and individuals primarily in Alaska. August 16th the company increased its quarterly dividend 13% to $0.17 per share. The dividend is payable Sept. 13 to shareholders of record as of the close of business on Sept. 5, 2013. The yield based on the new payout is 2.8%.
Top 10 High Tech Companies To Buy For 2014: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion:- [By Brian Orelli]
Imbruvica, which Johnson & Johnson developed with Pharmacyclics (NASDAQ: PCYC ) , is already approved in the U.S. to treat mantle cell lymphoma and chronic lymphocytic leukemia. The duo is also testing the drug in diffuse large B-cell lymphoma, multiple myeloma, follicular lymphoma, and Waldenstrom's macroglobulinemia.
Top 10 High Tech Companies To Buy For 2014: Arabian American Development Co (ARSD)
Arabian American Development Company, incorporated in 1967, is engaged in manufacturing various specialty petrochemical products. As of December 31, 2011, the Company owned a 37% interest in Al Masane Al Kobra Mining Company and a 55% interest in Pioche Ely Valley Mines, Inc (PEVM). The Company�� United States activities are primarily conducted through a wholly owned subsidiary, Texas Oil and Chemical Co. II, Inc. (TOCCO). TOCCO owns of South Hampton Resources Inc. (South Hampton), and South Hampton owns of Gulf State Pipe Line Company, Inc. (Gulf State).
South Hampton owns and operates a specialty petrochemical facility near Silsbee, Texas, which produces petrochemical solvents and other petroleum based products, including isopentane, normal pentane, isohexane and hexane, which is used in the production of polyethylene, packaging, polypropylene, expandable polystyrene, poly-iso/urethane foams, and in the catalyst support industry. Gulf State owns and operates three pipelines that connect the South Hampton facility to a natural gas line, to South Hampton�� truck and rail loading terminal and to a petroleum products pipeline owned by an unaffiliated third party.
South Hampton owns and operates a specialty petrochemical facility near Silsbee, Texas which is approximately 30 miles north of Beaumont, Texas, and 90 miles east of Houston. The facility consists of seven operating units which, while interconnected, make distinct products through differing processes: a Penhex Unit; a Reformer; a Cyclo-pentane Unit; an Aromax Unit; an Aromatics Hydrogenation Unit; a White Oil Fractionation Unit, and a Hydrocarbon Processing Demonstration Unit.
Gulf State owns and operates three 8-inch diameter pipelines aggregating approximately 50 miles in length connecting South Hampton�� facility to: a natural gas line, South Hampton�� truck and rail loading terminal and a petroleum products pipeline system owned by an unaffiliated third party. The Penhex Unit has the capacity! to process approximately 6,700 barrels per day, with the Reforming Unit, the Aromax Unit, and the Cyclo-Pentane Unit further processing streams produced by the Penhex Unit. The Aromatics Hydrogenation Unit has a capacity of approximately 400 barrels per day, and the White Oils Fractionation Unit has a capacity of approximately 3,000 barrels per day. The Hydrocarbon Processing Demonstration Unit has a capacity of approximately 300 gallons per day. The facility generally consists of equipment commonly found in petrochemical facilities, such as fractionation towers and hydrogen treaters except the facility is adapted to produce specialized products. South Hampton produces eight distinct product streams and markets several combinations of blends as needed in various customers��applications.
The Reformer and Aromax units are operated as needed to support the Penhex and Cyclo-pentane Units. The other two operating units at the plant site, an Aromatics Hydrogenation Unit and a White Oils Fractionation Unit, are operated as two, independent and completely segregated processes. These units are dedicated to the needs of two different toll processing customers. Products may be sold directly from South Hampton�� storage tanks or transported to the customers��location for storage and marketing. South Hampton, in support of the petrochemical operation, owns approximately 75 storage tanks with total capacity approaching 225,000 barrels, and 95 acres of land at the plant site, 55 acres of which are developed. South Hampton also owns a truck and railroad loading terminal consisting of storage tanks, four rail spurs, and truck and tank car loading facilities on approximately 53 acres of which 13 acres are developed.
The Company�� mineral interest in the United States is its 55% ownership interest in an inactive corporation, PEVM. PEVM�� properties include 48 patented and 5 unpatented claims totaling approximately 1,500 acres. All of the claims are located in Lincoln County, Nevada.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Arabian American Development (NYSE: ARSD ) , whose recent revenue and earnings are plotted below.
Top 10 High Tech Companies To Buy For 2014: Ram Resources Ltd (RMR)
Ram Resources Limited is an Australia-based company. The Company is engaged in exploration of mineral properties in Greenland and Western Australia. The Company�� Motzfeld Project is located in South Greenland, some 24 kilometers from the town of Narsarsuaq and comprises exploration licences 2010/46 and 2011/24. The Company holds 51% interest in the Motzfeldt project. The Romney (EL 2010/46) located in the Lejrelev Valley about 3.5 kilometers to the west of the Aries prospect. The Merino forms a steep-sided ridge at the north-eastern end of this valley, about 2.5 kilometers to the north-north-west of Aries. The Company�� Voskop Prospect is located within Exploration Licence 2011/24 in the Storeelv Valley about 7 kilometers to the northwest of the Company�� Aries target. The Drysdale Prospect is located on top of a broad ridge about 7.5 kilometers southeast of Aries and at an elevation of about 1,600 meter. Advisors' Opinion:- [By Chris DeMuth Jr.]
To use a recent REIT example, take CommonWealth REIT. This is a large well established REIT that is valued in the market with one of the lowest multiples of FFO in the industry. The reason the company trades at a multiple roughly half its competitors, in my opinion, is the poorly aligned management incentive structure. The management of CommonWealth is contracted to an external management firm, Reit Management Research (RMR). Many of the trustees of CommonWeath are owners of RMR and serve on both boards. RMR is primarily compensated by growing CWH's assets which are under RMR's management, not on stock price, FFO, or anything else that is closely aligned to generating shareholder returns. This has the perverse effect of motivating them to issue lots of equity and buy lots of buildings irrespective of the value add to CommonWealth shareholders. Neither the management company nor its employees have a significant amount of their income based on the performance of CommonWealth's stock price. This has resulted in an activist, Corvex Capital, buying a significant position in the company and taking action to replace the board and the management team. The proxy advisory firm, ISS, has sided with the activist and recommended that shareholders vote out the current trustees. ISS notes, "Between 2007-2012 …while the CommonWealth management team increased assets by 198% of period-ending market cap - driving a significant increase in fees payable to management - Commonwealth's share price - the measure of value appreciation for shareholders - fell by 68%." This is the poster child of misaligned management incentives.
Top 10 High Tech Companies To Buy For 2014: Avanir Pharmaceuticals Inc(AVNR)
Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. The company primarily offers NUEDEXTA, a unique proprietary combination of dextromethorphan and low-dose quinidine for the treatment of pseudobulbar affect. Its product line also comprises AVP-923 in Phase II clinical trial for the treatment of central neuropathic pain in patients with multiple sclerosis; and in Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. In addition, the company provides Docosanol 10% cream, an over-the-counter product for cold sores treatment. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.
Advisors' Opinion:- [By Rebecca McClay]
Finally, Avanir Pharmaceuticals Inc. (Nasdaq: AVNR) is up about 7% today after it settled with Actavis South Atlantic and Actavis Inc. (NYSE: ACT) to resolve pending patent litigation regarding ACT's seeking approval to market generic versions of AVNR's NUEDEXTA capsules. ACT is up about 1%.
- [By Keith Speights]
Avanir Pharmaceuticals (NASDAQ: AVNR ) reported its fiscal second-quarter results after the market closed on Wednesday. Here are the key points that investors need to know.
